{"id":11829,"date":"2023-03-27T09:25:34","date_gmt":"2023-03-27T13:25:34","guid":{"rendered":"https:\/\/dbv-technologies.com\/?post_type=press_releases&#038;p=11829"},"modified":"2023-04-21T12:51:26","modified_gmt":"2023-04-21T16:51:26","slug":"assemblee-generale-mixte-du-12-avril-2023","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/assemblee-generale-mixte-du-12-avril-2023\/","title":{"rendered":"Assembl\u00e9e G\u00e9n\u00e9rale Mixte du 12 avril 2023"},"content":{"rendered":"<div id=\"main-body-container\" class=\"main-body-container article-body \">\n<p align=\"right\">Montrouge, France, le 24 mars (21h 30 CET) 2023<\/p>\n<div id=\"quote-carousel-container-body\"><\/div>\n<p align=\"justify\"><strong>Assembl\u00e9e G\u00e9n\u00e9rale Mixte du <\/strong><strong>12<\/strong> <strong>avril<\/strong><strong> 202<\/strong><strong>3<\/strong><\/p>\n<p align=\"justify\"><strong>Modalit\u00e9s de mise \u00e0 disposition des <\/strong><strong>informations et <\/strong><strong>documents pr\u00e9paratoires \u00e0 l\u2019Assembl\u00e9e<\/strong><strong> G\u00e9n\u00e9rale<\/strong><\/p>\n<p align=\"justify\">DBV Technologies (Euronext : DBV \u2013 ISIN : FR0010417345 \u2013 NASDAQ : DBVT), soci\u00e9t\u00e9 biopharmaceutique fran\u00e7aise au stade clinique, tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le mercredi 12 avril \u00e0 10h00 (heure de Paris), au si\u00e8ge de la Soci\u00e9t\u00e9, 177-181 Avenue Pierre Brossolette \u00e0 Montrouge (92120).<\/p>\n<p align=\"justify\">L\u2019avis de r\u00e9union comportant l\u2019ordre du jour, les projets de r\u00e9solutions et les modalit\u00e9s de participation \u00e0 l\u2019Assembl\u00e9e G\u00e9n\u00e9rale a \u00e9t\u00e9 publi\u00e9 au BALO du 8 mars 2023 (n\u00b0 2300429). L\u2019avis de convocation a \u00e9t\u00e9 publi\u00e9 au BALO du 24 mars 2023 (n\u00b0 2300600) et dans les Affiches parisiennes le 24 mars 2023.<\/p>\n<p align=\"justify\">Les informations et documents pr\u00e9paratoires \u00e0 cette Assembl\u00e9e sont mis \u00e0 la disposition des actionnaires de la Soci\u00e9t\u00e9 selon les modalit\u00e9s et dans les d\u00e9lais pr\u00e9vus par les dispositions l\u00e9gales et r\u00e9glementaires applicables. Les documents vis\u00e9s \u00e0 l\u2019article R.22-10-23 du Code de commerce sont disponibles sur le site internet de la Soci\u00e9t\u00e9 (<a title=\"www.dbv-technologies.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=9NtBd4PG1CUKyCWLItmeHrqP8IKPILWd1-A9sFdsWmAKIsH9pjrKbHQkNtFPa6kMpQWTdE94pM50yponpoLbhWJOniIfwa4PQ5yX91jgR3U=\" target=\"_blank\" rel=\"nofollow noopener\">www.dbv-technologies.com<\/a>).<\/p>\n<p align=\"justify\">Tout actionnaire souhaitant recevoir ces documents par voie postale ou par voie \u00e9lectronique peut en faire la demande jusqu\u2019au cinqui\u00e8me jour avant l\u2019Assembl\u00e9e G\u00e9n\u00e9rale, soit jusqu\u2019au vendredi 7 avril 2023 \u00e0 minuit, heure de Paris, directement sur l\u2019adresse mail d\u00e9di\u00e9e de la Soci\u00e9t\u00e9\u00a0: <a title=\"investors@dbv-technologies.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=6TuAfU1n5zcQInYTE64MESCOjn5YaGFICnTMXggy7SBbq0OzM62KVFBb6wVf-TBaCFiIV2gwrlqyDjj2x3DR1UArqpcO3BXWBJEt78O-tCHd4qGSpTclJFXridu2_JR9\" target=\"_blank\" rel=\"nofollow noopener\">investors@dbv-technologies.com<\/a>. Pour<br \/>\nles actionnaires au porteur, cette demande devra \u00eatre accompagn\u00e9e d\u2019une attestation d\u2019inscription dans les comptes-titres tenus par un interm\u00e9diaire mentionn\u00e9 \u00e0 l&rsquo;article L. 211-3 du Code mon\u00e9taire et financier.<\/p>\n<p align=\"justify\"><strong>Retransmission de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale<\/strong><\/p>\n<p align=\"justify\">Mercredi 12 avril 2023, \u00e0 compter de 10h00 (heure de Paris), l\u2019Assembl\u00e9e G\u00e9n\u00e9rale fera l\u2019objet d\u2019une retransmission en direct sur le site de la Soci\u00e9t\u00e9 <a title=\"www.dbv-technologies.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=9NtBd4PG1CUKyCWLItmeHrqP8IKPILWd1-A9sFdsWmCERuc1c8tnaBIilOrmPT-mCeeOn_iWT8I73yVxW44P7Y2Sa9gJtvVeFKwpf3wW_4U=\" target=\"_blank\" rel=\"nofollow noopener\">www.dbv-technologies.com<\/a>.<\/p>\n<p align=\"justify\">Les actionnaires pourront \u00e9galement avoir acc\u00e8s \u00e0 la retransmission en diff\u00e9r\u00e9 de l\u2019Assembl\u00e9e sur le site de la Soci\u00e9t\u00e9 pendant les deux ans suivant la tenue de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale.<\/p>\n<p align=\"justify\"><strong>A propos de DBV Technologies\u00a0<\/strong><br \/>\nDBV Technologies d\u00e9veloppe Viaskin\u2122, une plateforme technologique exclusive exp\u00e9rimentale avec de larges applications potentielles en immunoth\u00e9rapie. Viaskin est bas\u00e9 sur l\u2019immunoth\u00e9rapie \u00e9picutan\u00e9e, ou EPIT\u2122, et constitue la m\u00e9thode de DBV Technologies pour d\u00e9livrer des compos\u00e9s biologiquement actifs au syst\u00e8me immunitaire \u00e0 travers la peau intacte. Avec cette nouvelle classe de produits candidats non invasifs, la Soci\u00e9t\u00e9 vise \u00e0 transformer en toute s\u00e9curit\u00e9 le traitement des patients souffrant d\u2019allergies alimentaires. Les programmes de DBV Technologies sur les allergies alimentaires comprennent des essais cliniques en cours sur Viaskin Peanut. Le si\u00e8ge mondial de DBV Technologies est situ\u00e9 \u00e0 Montrouge, en France, et ses op\u00e9rations nord-am\u00e9ricaines sont bas\u00e9es \u00e0 Basking Ridge, NJ. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris (symbole : DBV, code ISIN : FR0010417345) et les ADS de la Soci\u00e9t\u00e9 (chacun repr\u00e9sentant une demi-action ordinaire) sont n\u00e9goci\u00e9s sur le Nasdaq Global Select Market (symbole : DBVT).<\/p>\n<p align=\"justify\"><strong>D\u00e9clarations prospectives <\/strong><br \/>\nLe pr\u00e9sent communiqu\u00e9 de presse peut contenir des d\u00e9clarations prospectives et des estimations, notamment des d\u00e9clarations concernant le potentiel th\u00e9rapeutique de Viaskin\u2122 Peanut en tant que traitement pour les enfants allergiques aux arachides et les avantages potentiels de l\u2019EPIT\u2122. Ces d\u00e9clarations et estimations prospectives ne constituent ni des promesses ni des garanties et comportent des risques et des incertitudes substantiels et celles-ci peuvent \u00eatre affect\u00e9s par les conditions du march\u00e9 ainsi que par d&rsquo;autres risques et incertitudes expos\u00e9s dans les documents r\u00e9glementaires d\u00e9pos\u00e9s par DBV Technologies aupr\u00e8s de l&rsquo;Autorit\u00e9 des March\u00e9s Financiers (\u00ab\u00a0AMF\u00a0\u00bb) ainsi que dans les documents et rapports d\u00e9pos\u00e9s par DBV Technologies aupr\u00e8s de la Securities and Exchange Commission (\u00ab\u00a0SEC\u00a0\u00bb) des \u00c9tats-Unis, et dans les documents et rapports futurs d\u00e9pos\u00e9s aupr\u00e8s de l&rsquo;AMF et de la SEC. Les investisseurs actuels et potentiels sont invit\u00e9s \u00e0 ne pas accorder une confiance excessive \u00e0 ces d\u00e9clarations et estimations prospectives, qui ne sont valables qu\u2019\u00e0 la date du pr\u00e9sent document. \u00c0 l\u2019exception de ce qui est requis par la loi applicable, DBV Technologies ne s\u2019engage nullement \u00e0 mettre \u00e0 jour ou \u00e0 r\u00e9viser les informations contenues dans le pr\u00e9sent communiqu\u00e9 de presse.<\/p>\n<p align=\"justify\"><strong>Contact investisseurs<\/strong><br \/>\nAnne\u00a0Pollak<br \/>\nDBV\u00a0Technologies<br \/>\n+1\u00a0857-529-2363<br \/>\n<a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=i5ZXNo27N4nbwNGSa3Vmic3pM9XHuKxudYwis2FyRZ44B5BAZNWoX4pLgTe8wCi65CsMy1aNWZtwJttaxpdj86appJrhu6aJ7MMSicYfCBuG9LdCy01K52oYrxaoIBpe\" target=\"_blank\" rel=\"nofollow noopener\"><u>anne.pollak@dbv-technologies.com<\/u><\/a><\/p>\n<p align=\"justify\"><strong>Contact m\u00e9dia<\/strong><br \/>\nAngela\u00a0Marcucci<br \/>\nDBV\u00a0Technologies<br \/>\n+1\u00a0646-842-2393<br \/>\n<u>angela.marcucci@dbv-technologies.com<\/u><\/p>\n<p id=\"gnw_attachments_section-header\"><strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li><a title=\"version PDF\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=9zKJiQOreLIt5sq9Us9LCWM654t5dfK5QB7H2ISqSWl0SY8mUZ6iR0_3cRFTo44YlG9pRFYEQPcMhUVON0pyPKuO1Ee3-bxGRejxYQimBDLuwQ4MIOvABQUlJKwSRO3S-iMzOcbvWceO-TGmlmopnUuFAU0CZ5VYvU41JqA_CYc=\" target=\"_blank\" rel=\"nofollow noopener\">version PDF<\/a><\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/OGNkMTA5MmYtMmE2MC00YzE2LTgyNWEtOWFiNzE1MjMxOTk1LTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" \/><\/p>\n<\/div>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[45],"class_list":["post-11829","press_releases","type-press_releases","status-publish","hentry","press_release_type-agm-document"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/11829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/11829\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=11829"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=11829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}